-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive.
Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and.
Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clinical-stage lead candidate INT-1B3 InteRNA Technologies, a clinical-stage
Common Scientific Advisory Board (SAB) between CRKI and KCCC
A common international Scientific Advisory Board between Cancer Research KI and the Karolinska Comprehensive Cancer Center (KCCC) has been established. The board of directors of the KCCC, representing both the Karolinska Institute and The Karolinska University Hospital, aimed to incorporate advisory members with broad expertise in clinical, basic and caring cancer research; covering a varied set of cancer subdisciplines.
This common SAB will be able to advise on matters including, but not limited to, the long-term strategic development of research, education, care and prevention within cancer for both Cancer Research KI and the CCC. The current members of the SAB are listed below in the table.